Procter & Gamble Pharmaceuticals

Actonel reduces vertebral, nonvertebral fracture risk

Published in Women's Health Law Weekly, November 7th, 2004

A new analysis shows that Actonel (risedronate sodium tablets) treatment up to 3 years significantly reduces the risk of vertebral and nonvertebral fragility fracture by 75% in postmenopausal women with osteopenia.

These data were presented during an oral presentation at The North American Menopause Society (NAMS) annual meeting.

"Postmenopausal women with a bone mineral density (BMD) score above the osteoporosis threshold could still be at risk of fracture since other factors besides low BMD contribute to fracture risk," said James A. Simon, clinical professor of obstetrics and gynecology at George Washington University, Washington, DC, and medical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Law Weekly

Source: Women's Health Law Weekly (2004-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry